Ratings Aclaris Therapeutics, Inc.

Equities

ACRS

US00461U1051

Market Closed - Nasdaq Other stock markets 01:30:00 03/05/2024 am IST			5-day change	1st Jan Change
1.31 ^USD	+3.97%		+10.08%	+24.76%

19/03	Aclaris Therapeutics, Inc. Announces Board Resignations	CI
27/02	Aclaris Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the past twelve months, EPS forecast has been revised upwards.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' opinions have been revised negatively.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ACLARIS THERAPEUTICS, INC.	+24.76%	89.79M	C-
MODERNA, INC.	+26.28%	42.68B	B-
IQVIA HOLDINGS INC.	-3.99%	42.4B	B
LONZA GROUP AG	+45.32%	40.04B	A
CELLTRION, INC.	-6.20%	28.31B	C
ICON PUBLIC LIMITED COMPANY	+6.36%	24.94B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.47%	18.96B	B
MEDPACE HOLDINGS, INC.	+27.58%	12.3B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.75%	11.95B	C+
BIO-TECHNE CORPORATION	-2.02%	11.55B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes